Get the Stockscreener App
2.25
0.88%
-0.02
After Hours:
2.25
Maxcyte Inc stock is traded at $2.25, with a volume of 334.87K.
It is down -0.88% in the last 24 hours and up +0.90% over the past month.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
See More
Previous Close:
$2.27
Open:
$2.26
24h Volume:
334.87K
Relative Volume:
0.39
Market Cap:
$239.44M
Revenue:
$45.44M
Net Income/Loss:
$-35.43M
P/E Ratio:
-6.6176
EPS:
-0.34
Net Cash Flow:
$-25.39M
1W Performance:
+11.39%
1M Performance:
+0.90%
6M Performance:
-51.72%
1Y Performance:
-51.30%
1-Day Range:
$2.18
$2.27
1-Week Range:
$2.02
$2.37
52-Week Range:
$2.00
$5.20
Maxcyte Inc Stock (MXCT) Company Profile
Name
Maxcyte Inc
Sector
Industry
Phone
301-517-5556
Address
9713 KEY WEST AVENUE,, ROCKVILLE
Compare MXCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
2.25 | 241.34M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
126.54 | 218.59B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.14 | 157.13B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
403.53 | 151.59B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
92.94 | 118.29B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
80.00 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-25 | Initiated | Stephens | Overweight |
| Nov-29-23 | Initiated | Craig Hallum | Buy |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-24-21 | Initiated | BTIG Research | Buy |
| Aug-24-21 | Initiated | Cowen | Outperform |
| Aug-24-21 | Initiated | Stephens | Overweight |
| Aug-24-21 | Initiated | Stifel | Buy |
| Aug-24-21 | Initiated | Wedbush | Outperform |
| Aug-24-21 | Initiated | William Blair | Outperform |
View All
Maxcyte Inc Stock (MXCT) Latest News
What drives MaxCyte Inc. stock priceHigh-yield investments - PrintWeekIndia
How MaxCyte Inc. stock performs during market volatilitySmart Growth Low Risk Picks - Newser
Is MaxCyte Inc. a good long term investmentHigh-return market picks - PrintWeekIndia
What makes MaxCyte Inc. stock attractive to long term investorsExceptional stock performance - jammulinksnews.com
What analysts say about MaxCyte Inc. stockRapid portfolio appreciation - Autocar Professional
MaxCyte Inc. Stock Analysis and ForecastSuperior risk-adjusted returns - Autocar Professional
Published on: 2025-07-23 21:52:41 - Autocar Professional
Why MaxCyte Inc. stock attracts strong analyst attentionHigh Potential Stock Ideas - Newser
What makes MaxCyte Inc. stock price move sharplySwing Trade Signals - Newser
IWN ETF Implied Analyst Target Price: $198.15 - AInvest
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025 - 富途牛牛
MaxCyte, Inc. to Release Second Quarter 2025 Financial Results on August 6th - Nasdaq
PHC announces exclusive distribution of MaxCyte ExPERT platform in Japan - BioSpectrum Asia
PHC TO EXCLUSIVELY DISTRIBUTE MAXCYTE CELL ENGINEERING PLATFORM IN JAPAN - bernama
Business Wire - JIJI PRESS
PHC Announces Exclusive Distribution of MaxCyte® ExPERT™ Platform in Japan - Business Wire
MaxCyte Cancels AIM Market Trading for Common Stock - TipRanks
MaxCyte shares trading for last time in London - Sharecast.com
Moving Gene Editing Advances Into the Clinic - the-scientist.com
MaxCyte stockholders approve AIM delisting, company to trade only on Nasdaq - Investing.com
MaxCyte Shareholders Approve Equity Plan Amendment - TipRanks
MaxCyte shareholders approve equity plan expansion, AIM delisting - Investing.com
Analyzing Ratios: MaxCyte Inc (MXCT)’s Financial Story Unveiled - DWinneX
Maxcyte Inc Stock (MXCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):